Enlivex Therapeutics Ltd. (ENLV)
NASDAQ: ENLV · Real-Time Price · USD
1.210
+0.050 (4.31%)
At close: Dec 5, 2025, 4:00 PM EST
1.180
-0.030 (-2.48%)
After-hours: Dec 5, 2025, 7:54 PM EST
Enlivex Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Enlivex Therapeutics stock has a target of 7.00, which predicts a 478.51% increase from the current stock price of 1.21.
Price Target: $7.00 (+478.51%)
Analyst Consensus: Buy
* Price targets were last updated on Sep 2, 2025.
Analyst Ratings
The average analyst rating for Enlivex Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 24, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +974.38% | Oct 29, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +974.38% | Sep 26, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $13 | Strong Buy | Maintains | $13 | +974.38% | Sep 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +478.51% | Sep 2, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.46
from -0.73
EPS Next Year
-0.58
from -0.46
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.47 | -0.60 | ||||
| Avg | -0.46 | -0.58 | ||||
| Low | -0.44 | -0.56 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.